PURPOSE: 7-Hydroxystaurosporine (UCN-01) is a protein kinase inhibitor that inhibits several serine-threonine kinases including PKC and PDK1. Due to the preclinical synergistic effects seen with topoisomerase I inhibitors and non-overlapping toxicity, UCN-01 and irinotecan were combined in a dose-finding study designed to determine the maximum tolerated dose (MTD), toxicity profile, and pharmacokinetics (PK) of UCN-01 and irinotecan. METHODS: Patients with incurable solid malignancies received UCN-01 intravenously (IV) as a 3-h infusion on day 1 and irinotecan IV over 90 min on days 1 and 8 of a 21-day cycle. Doses of UCN-01 for subsequent cycles were half the starting dose. Dose level 1 (DL1) consisted of UCN-01 and irinotecan doses of 50 and 60 mg/m(2), respectively. Blood samples were collected in cycle 1 for UCN-01, irinotecan, and irinotecan metabolites. RESULTS: A total of 16 patients were enrolled on the trial at UCN-01/Irinotecan doses of 50/60 mg/m(2) (DL1; n = 1), 70/60 mg/m(2) (DL2; n = 6), 90/60 mg/m(2) (DL3; n = 4), and 70/90 mg/m(2) (DL4; n = 5). Two dose-limiting toxicities were observed each in DL3 and DL4 (2 grade 3 hypophosphatemia, 1 grade 4 hyperglycemia and grade 3 hypophosphatemia, 1 grade 4 febrile neutropenia). Fatigue, diarrhea, nausea, and anorexia were the most prevalent toxicities. No objective responses were documented, and four patients had stable disease for at least ten cycles. The long half-life (292.0 +/- 135.7 h), low clearance (0.045 +/- 0.038 l/h), and volume of distribution (14.3 +/- 5.9 l) observed for UCN-01 are consistent with prior UCN-01 data. There was a significant decrease in C(max) of APC, AUC of APC and SN-38, and AUC ratio of SN-38:irinotecan when comparing days 1 and 8 PK. CONCLUSIONS: APC and SN-38 exposure decreased when administered in combination with UCN-01. The MTD of the combination based on protocol criteria was defined as 70 mg/m(2) of UCN-01 on day 1 and 60 mg/m(2) of irinotecan on days 1 and 8 in a 21-day cycle.
PURPOSE:7-Hydroxystaurosporine (UCN-01) is a protein kinase inhibitor that inhibits several serine-threonine kinases including PKC and PDK1. Due to the preclinical synergistic effects seen with topoisomerase I inhibitors and non-overlapping toxicity, UCN-01 and irinotecan were combined in a dose-finding study designed to determine the maximum tolerated dose (MTD), toxicity profile, and pharmacokinetics (PK) of UCN-01 and irinotecan. METHODS:Patients with incurable solid malignancies received UCN-01 intravenously (IV) as a 3-h infusion on day 1 and irinotecan IV over 90 min on days 1 and 8 of a 21-day cycle. Doses of UCN-01 for subsequent cycles were half the starting dose. Dose level 1 (DL1) consisted of UCN-01 and irinotecan doses of 50 and 60 mg/m(2), respectively. Blood samples were collected in cycle 1 for UCN-01, irinotecan, and irinotecan metabolites. RESULTS: A total of 16 patients were enrolled on the trial at UCN-01/Irinotecan doses of 50/60 mg/m(2) (DL1; n = 1), 70/60 mg/m(2) (DL2; n = 6), 90/60 mg/m(2) (DL3; n = 4), and 70/90 mg/m(2) (DL4; n = 5). Two dose-limiting toxicities were observed each in DL3 and DL4 (2 grade 3 hypophosphatemia, 1 grade 4 hyperglycemia and grade 3 hypophosphatemia, 1 grade 4 febrile neutropenia). Fatigue, diarrhea, nausea, and anorexia were the most prevalent toxicities. No objective responses were documented, and four patients had stable disease for at least ten cycles. The long half-life (292.0 +/- 135.7 h), low clearance (0.045 +/- 0.038 l/h), and volume of distribution (14.3 +/- 5.9 l) observed for UCN-01 are consistent with prior UCN-01 data. There was a significant decrease in C(max) of APC, AUC of APC and SN-38, and AUC ratio of SN-38:irinotecan when comparing days 1 and 8 PK. CONCLUSIONS:APC and SN-38 exposure decreased when administered in combination with UCN-01. The MTD of the combination based on protocol criteria was defined as 70 mg/m(2) of UCN-01 on day 1 and 60 mg/m(2) of irinotecan on days 1 and 8 in a 21-day cycle.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: P R Graves; L Yu; J K Schwarz; J Gales; E A Sausville; P M O'Connor; H Piwnica-Worms Journal: J Biol Chem Date: 2000-02-25 Impact factor: 5.157
Authors: E A Sausville; S G Arbuck; R Messmann; D Headlee; K S Bauer; R M Lush; A Murgo; W D Figg; T Lahusen; S Jaken; X Jing ; M Roberge; E Fuse; T Kuwabara; A M Senderowicz Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: J Usuda; N Saijo; K Fukuoka; H Fukumoto; H J Kuh; T Nakamura; Y Koh; T Suzuki; F Koizumi; T Tamura; H Kato; K Nishio Journal: Int J Cancer Date: 2000-01-15 Impact factor: 7.396
Authors: Qiang Yu; JiHyun La Rose; Hongliang Zhang; Haruyuki Takemura; Kurt W Kohn; Yves Pommier Journal: Cancer Res Date: 2002-10-15 Impact factor: 12.701
Authors: Diederik F S Kehrer; Ron H J Mathijssen; Jaap Verweij; Peter de Bruijn; Alex Sparreboom Journal: J Clin Oncol Date: 2002-07-15 Impact factor: 44.544
Authors: Ron H J Mathijssen; Jaap Verweij; Peter de Bruijn; Walter J Loos; Alex Sparreboom Journal: J Natl Cancer Inst Date: 2002-08-21 Impact factor: 13.506
Authors: Christina Antonopoulos; Caroline El Sanadi; William J Kaiser; Edward S Mocarski; George R Dubyak Journal: J Immunol Date: 2013-09-27 Impact factor: 5.422
Authors: Nadeem Khan; Sriram P Mupparaju; Huagang Hou; Jean P Lariviere; Eugene Demidenko; Harold M Swartz; Alan Eastman Journal: Radiat Res Date: 2009-11 Impact factor: 2.841
Authors: Luis G Vargas Buonfiglio; Mosaab Bagegni; Jennifer A Borcherding; Jessica C Sieren; Juan C Caraballo; Andrew Reger; Joseph Zabner; Xiaopeng Li; Alejandro P Comellas Journal: Am J Respir Cell Mol Biol Date: 2016-12 Impact factor: 6.914
Authors: Nilofer Azad; Arvind Dasari; John Arcaroli; Gretchen E Taylor; Daniel A Laheru; Michael A Carducci; Martine McManus; Kevin Quackenbush; John J Wright; Manuel Hidalgo; Luis A Diaz; Ross C Donehower; Ming Zhao; Michelle A Rudek; Wells A Messersmith Journal: Invest New Drugs Date: 2012-05-22 Impact factor: 3.850
Authors: Shivaani Kummar; Martin E Gutierrez; Erin R Gardner; William D Figg; Giovanni Melillo; Janet Dancey; Edward A Sausville; Barbara A Conley; Anthony J Murgo; James H Doroshow Journal: Cancer Chemother Pharmacol Date: 2009-11-06 Impact factor: 3.333